Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Sarepta Winning Payer War Over Duchenne Muscular Dystrophy Drug Coverage

Mar 02 2017

• By Derrick Gingery

Related Content

J.P. Morgan Notebook Day 2: Bristol Humbled By Competition, Sanofi’s Sarilumab Ready For Review, Justifying Spinraza’s Price And More

Jan 11 2017

Sarepta Eyes Patient Outcomes To Boost Exondys 51's European Review

Jan 28 2017

Sarepta Must Balance Exondys 51 Confirmatory Trials And Sales

Sep 23 2016

Amid Pricing Criticism, Marathon 'Pausing' Emflaza Launch

Feb 13 2017

Patients Can't Rescue Sarepta's Eteplirsen

Apr 26 2016

Anthem Denies Coverage For Eteplirsen, Citing Lack Of Clinical Efficacy

Oct 07 2016

Sarepta's Eteplirsen Approved After Contentious Internal FDA Debate

Sep 20 2016

No More Sarepta-Like Development, FDA Officials Say

Oct 20 2016

Sarepta's Shadow: BioMarin Mulls Turning The Extraordinary Into A Template

Oct 15 2016

Exondys 51’s Development: Was Placebo-Controlled Trial Possible?

Nov 16 2016

Related Companies

Sarepta Therapeutics, Inc.

Anthem Inc.

BioMarin Pharmaceutical Inc.

PTC Therapeutics, Inc.

Marathon Pharmaceuticals LLC

Additional Topics

United States Reimbursement Rare Diseases Commercial Business Strategies BioPharmaceutical

More from Drug Pricing

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window